Poster Oral Presentation 2

[PO-015] The impact of etrasimod on the transcriptome in colon biopsies using RNA-seq: data from ELEVATE UC 52 and ELEVATE UC 12 phase 3 clinical trials

Dana Verbovsky, Britta Siegmund^1,2, Rathi D Ryan³, Catherine M Crosby⁴, Maria T Abreu⁵, Séverine Vermeire⁶, Iris Dotan^7,8, Keren M Rabinowitz^7,9, Xiang Guo¹⁰, H Kiyomi Komori¹¹, Martina Goetsch¹², *Karolina Wosik¹³, John C Woolcott¹⁰, Silvio Danese¹⁴ (1. Med. Klinik für Gastroenterologie, Infektiologie, Rheumatologie, Charité – Universitätsmedizin Berlin, Berlin, Germany, 2. Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany, 3. Pfizer Inc, San Francisco, CA, USA, 4. Pfizer Inc, La Jolla, San Diego, CA, USA, 5. F. Widjaja Inflammatory Bowel Disease Institute, Cedars-Sinai, Los Angeles, CA, USA, 6. Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, 7. Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel, 8. Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel, 9. Felsentstein Medical Research Centre, Medical and Health Sciences, Tel Aviv, Israel, 10. Pfizer Inc, Collegeville, PA, USA, 11. Formerly Arena Pharmaceuticals, San Diego, CA, USA; a wholly-owned subsidiary of Pfizer Inc, New York, NY, USA, 12. Pfizer AG, Zürich, Switzerland, 13. Pfizer Canada, Kirkland, QC, Canada, 14. Division of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy)

Password required to view

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.